TargetMol

Trioxifene mesylate

Product Code:
 
TAR-T26295
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26295-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Trioxifene mesylate is an antiestrogen that suppresses growth hormone secretion.
CAS:
68307-81-3
Formula:
C60H64N2O8S
Molecular Weight:
973.24
Purity:
0.98
SMILES:
CS(O)(=O)=O.COc1ccc(cc1)C1=C(c2ccccc2CC1)c1cc(OCCN2CCCC2)ccc1C(=O)c1ccc(OCCN2CCCC2)cc1C1=C(CCc2ccccc12)c1ccc(OC)cc1

References

1. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 1;57(1):40-3. PubMed PMID: 3940620. 2. Arafah B, Manni A, Pearson OH. Trioxifene mesylate (LY 133314): a new antiestrogen which inhibits growth hormone secretion in the rat. Eur J Cancer. 1980;Suppl 1:281-5. PubMed PMID: 7032941. 3. Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, Falkson G, Carbone PP, Ramirez G, Falkson H, Pretorius FJ. A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects. Cancer. 1986 Jan 1;57(1):34-9. PubMed PMID: 3079661. 4. Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA, Jones CD, Krishnan V, Lynch R, Osborne HE, Graff JR. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Res. 2003 Sep 15;63(18):6056-62. PubMed PMID: 14522935.